E

Tagging the Donkey

Will in vivo CAR-T cell therapies go prime time?

November 2, 2023
E

Wow, just wow!

When an established concept is finally coming of age with new colours...

August 3, 2023
E

An emerging opportunity in the CAR-T cell therapy space

Taking a different approach to CAR design with some positive data to show for it

August 2, 2023
E

Standing out from the crowd in AML

Encouraging new developments in the CAR-NK niche

June 27, 2023
E

Chemistry in context – next generation cell therapies

Opportunities and challenges abund for several next-gen CAR-T cell therapies

May 25, 2023
E

From far away you see more

Next generation CAR-T cell therapies for solid tumours

May 22, 2023
E

A cluster of new developments

What's new on the CAR-T cell therapy front?

May 5, 2023
E

Up and coming cell therapy companies to watch out for

What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?

May 24, 2022
E

Potential of Immunometabolism to Enhance CAR T cell therapy

How can we use metabolic reprogramming to enhance CAR T cell therapy?

August 18, 2020
E

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020
E

Engineering Immunity – what did we learn from ASGCT20?

There are some creative and innovative new CAR T cell therapy designs being developed - what are they and where will they be tested?

May 14, 2020
E

ASGCT20 Gems from the ePoster Hall

Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20

May 14, 2020
E

The Potential of CAR-NK Cells for Cancer Immunotherapy

Will CAR-NK cells follow CAR-T cell therapies and hit prime time?

May 13, 2020
E
Dr Holbrook Kohrt

Holbrook Kohrt Leads the Way in Targeting CD137

Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).

September 15, 2015
E

Adoptive Cell Therapies – an interview with Dr Carl June

Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours

August 14, 2015
E

Adoptive Cell Therapy: An Interview with Dr Steven Rosenberg

We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...

August 12, 2015
E

Oncolytic viruses – are they ready for prime time?

Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?

August 6, 2015
E

Juno and Celgene’s unexpected CAR-T cell and TCR collaboration

Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?

June 30, 2015
E

Suicide Genes – what are they and are they really needed?

Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?

May 28, 2015
E

New therapies for multiple myeloma may make an impact

Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma

May 18, 2015
E

Tom Gajewski takes the STING out of Cancer

Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.

May 13, 2015
E

Promise of Cancer Immunotherapy highlighted at Immunology 2015

At the 2015 annual meeting of the American Association of Immunologists (AAI) in New Orleans, leading experts shared their insights on the “Promise of Cancer Immunotherapy."

May 11, 2015